StemRIM (4599.T)
JPY 290.0
(-0.68%)
JPY 290.0
(-0.68%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 9.08 Billion JPY | -15.19% |
| 2023 | 10.7 Billion JPY | 11.56% |
| 2022 | 9.59 Billion JPY | -12.03% |
| 2021 | 10.9 Billion JPY | -3.3% |
| 2020 | 11.28 Billion JPY | 319.72% |
| 2019 | 2.68 Billion JPY | 39.64% |
| 2018 | 1.92 Billion JPY | 84.45% |
| 2017 | 1.04 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.06 Billion JPY | -1.61% |
| 2024 Q1 | 10.22 Billion JPY | -4.49% |
| 2024 Q4 | 9.08 Billion JPY | -5.25% |
| 2024 Q3 | 9.58 Billion JPY | -4.74% |
| 2023 Q3 | 11.18 Billion JPY | 22.94% |
| 2023 Q2 | 9.1 Billion JPY | -2.19% |
| 2023 Q4 | 10.7 Billion JPY | -4.3% |
| 2023 Q1 | 9.3 Billion JPY | -3.06% |
| 2023 FY | 10.7 Billion JPY | 11.56% |
| 2022 Q3 | 9.95 Billion JPY | -3.44% |
| 2022 Q2 | 10.31 Billion JPY | -2.58% |
| 2022 Q1 | 10.58 Billion JPY | -2.96% |
| 2022 Q4 | 9.59 Billion JPY | -3.62% |
| 2022 FY | 9.59 Billion JPY | -12.03% |
| 2021 Q4 | 10.9 Billion JPY | 8.1% |
| 2021 FY | 10.9 Billion JPY | -3.3% |
| 2021 Q1 | 10.9 Billion JPY | -3.29% |
| 2021 Q3 | 10.09 Billion JPY | -5.46% |
| 2021 Q2 | 10.67 Billion JPY | -2.16% |
| 2020 Q4 | 11.28 Billion JPY | 12.47% |
| 2020 Q2 | 9.97 Billion JPY | -2.06% |
| 2020 Q1 | 10.18 Billion JPY | 278.8% |
| 2020 FY | 11.28 Billion JPY | 319.72% |
| 2020 Q3 | 10.03 Billion JPY | 0.58% |
| 2019 Q4 | 2.68 Billion JPY | -8.29% |
| 2019 Q3 | 2.93 Billion JPY | 0.0% |
| 2019 FY | 2.68 Billion JPY | 39.64% |
| 2018 FY | 1.92 Billion JPY | 84.45% |
| 2017 FY | 1.04 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -37.799% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -649.53% |
| GNI Group Ltd. | 62.39 Billion JPY | 85.447% |
| Linical Co., Ltd. | 18.53 Billion JPY | 51.025% |
| Trans Genic Inc. | 9.81 Billion JPY | 7.451% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -61.16% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -30.72% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -56.112% |
| AnGes, Inc. | 28.89 Billion JPY | 68.573% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -946.957% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 94.224% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -460.985% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -79.048% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -108.741% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -273.224% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -282.578% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -31.019% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -418.426% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -78.545% |
| PeptiDream Inc. | 67.12 Billion JPY | 86.473% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -344.968% |
| Ribomic Inc. | 3.54 Billion JPY | -155.972% |
| SanBio Company Limited | 5.04 Billion JPY | -79.898% |
| Healios K.K. | 15.15 Billion JPY | 40.086% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -638.057% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -201.061% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -515.946% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -31.982% |
| FunPep Company Limited | 2.49 Billion JPY | -264.493% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -246.743% |
| Stella Pharma Corporation | 3.82 Billion JPY | -137.658% |
| TMS Co., Ltd. | 3.55 Billion JPY | -155.433% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -57.122% |
| Cuorips Inc. | 6.18 Billion JPY | -46.813% |
| K Pharma,Inc. | 3.31 Billion JPY | -173.997% |
| Takara Bio Inc. | 123.2 Billion JPY | 92.63% |
| ReproCELL Incorporated | 9.05 Billion JPY | -0.302% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -234.399% |
| StemCell Institute Inc. | 6.54 Billion JPY | -38.773% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -29.923% |
| CellSeed Inc. | 2.46 Billion JPY | -268.242% |